Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Jindal Steel & Power And Two More Indian Exchange Stocks Considered Below Estimated Intrinsic Values

In This Article:

The Indian stock market has experienced a notable fluctuation, declining by 1.3% over the past week, yet showing a robust increase of 43% over the past year with earnings expected to grow by 16% annually. In this context, identifying stocks like Jindal Steel & Power that are considered undervalued relative to their intrinsic values could be particularly compelling for investors looking for potential growth opportunities in a generally bullish market.

Top 10 Undervalued Stocks Based On Cash Flows In India

Name

Current Price

Fair Value (Est)

Discount (Est)

HEG (NSEI:HEG)

₹2125.10

₹3307.40

35.7%

KSB (BSE:500249)

₹996.45

₹1608.57

38.1%

IOL Chemicals and Pharmaceuticals (BSE:524164)

₹412.80

₹636.71

35.2%

Updater Services (NSEI:UDS)

₹315.65

₹538.46

41.4%

Vedanta (NSEI:VEDL)

₹430.90

₹720.33

40.2%

Rajesh Exports (NSEI:RAJESHEXPO)

₹316.50

₹508.95

37.8%

Mahindra Logistics (NSEI:MAHLOG)

₹515.30

₹854.52

39.7%

Strides Pharma Science (NSEI:STAR)

₹989.20

₹1664.05

40.6%

Delhivery (NSEI:DELHIVERY)

₹379.75

₹750.97

49.4%

Godrej Properties (NSEI:GODREJPROP)

₹3099.15

₹5526.09

43.9%

Click here to see the full list of 19 stocks from our Undervalued Indian Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Jindal Steel & Power

Overview: Jindal Steel & Power Limited is a company engaged in the steel, mining, and infrastructure sectors both in India and globally, with a market capitalization of approximately ₹99.20 billion.

Operations: The firm's operations span steel production, mining activities, and infrastructure development across both domestic and international markets.

Estimated Discount To Fair Value: 25.4%

Jindal Steel & Power Limited, trading at ₹937.8, is considered undervalued based on discounted cash flow analysis, with a fair value estimate of ₹1257.66. Despite a recent drop in net income to INR 13,401.5 million from INR 16,869.4 million year-over-year for Q1 2025, the company's earnings have grown by 95% over the past year and are projected to increase by 24.02% annually. Additionally, Jindal Steel's revenue growth is expected to outpace the Indian market average at 14.4% per year compared to 9.5%. However, its Return on Equity is forecasted to be low at around 15.3% in three years' time.

NSEI:JINDALSTEL Discounted Cash Flow as at Jul 2024
NSEI:JINDALSTEL Discounted Cash Flow as at Jul 2024

Piramal Pharma

Overview: Piramal Pharma Limited is a global pharmaceutical company with operations in North America, Europe, Japan, India, and other international markets, boasting a market capitalization of approximately ₹220.80 billion.